About this Research Topic
In the past decades, we have observed a dramatic increase in the number of people affected by age-related macular degeneration (AMD) worldwide, becoming the first cause of vision impairment of elderly people in western countries. To achieve better patient management, we will need to work to better implement our knowledge of the early diagnosis and treatments of this disease.
Recently, the introduction in the research setting and in clinical practice of new high-resolution non-invasive imaging devices (i.e. high-resolution structural optical coherence tomography [OCT] and OCT-Angiography [OCT-A]) has allowed us to better investigate several clinical aspects in the pathogenesis, diagnosis, and treatment of AMD. In detail, a crucial role is played by the identification of new biomarkers. Indeed, the identification of imaging biomarkers could be very useful for the correct early diagnosis and management of AMD patients.
In this Research Topic, we would like to describe new insights into the management of AMD, from pathophysiology to early diagnosis and clinical management. We hope to compile the latest research on, and clinical applications of, multimodal imaging examinations in the diagnosis and treatment of AMD.
This Research Topic aims to create a multidisciplinary forum of discussion about new insights in the management (i.e. diagnosis and treatment) of AMD. In detail, for this Research Topic we welcome submissions of Original Research, Brief Research Reports, Case Reports, and Reviews of exceptional merit addressing one or more of the following topics:
• Identification of multimodal imaging biomarkers in the early diagnosis of AMD
• Identification of multimodal imaging biomarkers useful in the management and follow-up of AMD
• Application of multimodal imaging in the understanding of the pathogenesis of AMD
• Clinical application of multimodal imaging in AMD
Topic Editor Srinivas R. Sadda received financial support from Bayer, Heidelberg Engineering, Topcon, Nidek. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Recently, the introduction in the research setting and in clinical practice of new high-resolution non-invasive imaging devices (i.e. high-resolution structural optical coherence tomography [OCT] and OCT-Angiography [OCT-A]) has allowed us to better investigate several clinical aspects in the pathogenesis, diagnosis, and treatment of AMD. In detail, a crucial role is played by the identification of new biomarkers. Indeed, the identification of imaging biomarkers could be very useful for the correct early diagnosis and management of AMD patients.
In this Research Topic, we would like to describe new insights into the management of AMD, from pathophysiology to early diagnosis and clinical management. We hope to compile the latest research on, and clinical applications of, multimodal imaging examinations in the diagnosis and treatment of AMD.
This Research Topic aims to create a multidisciplinary forum of discussion about new insights in the management (i.e. diagnosis and treatment) of AMD. In detail, for this Research Topic we welcome submissions of Original Research, Brief Research Reports, Case Reports, and Reviews of exceptional merit addressing one or more of the following topics:
• Identification of multimodal imaging biomarkers in the early diagnosis of AMD
• Identification of multimodal imaging biomarkers useful in the management and follow-up of AMD
• Application of multimodal imaging in the understanding of the pathogenesis of AMD
• Clinical application of multimodal imaging in AMD
Topic Editor Srinivas R. Sadda received financial support from Bayer, Heidelberg Engineering, Topcon, Nidek. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Macular degeneration, AMD, vision impairment, OCT, biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
